5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of treatment line on outcomes with salvage ipilimumab plus nivolumab in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Kotecha, R.; Lee, C. H.; Knezevic, A.; Shah, N. J.; Carlo, M. I.; Feldman, D. R.; Patil, S.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Kelly, W. K.; Danila, D. C.; Edenfield, W. J.; Aggarwal, R. R.; Petrylak, D. P.; Sartor, A. O.; Sumey, C. J.; Dorff, T. B.; Yu, E. Y.; Adra, N.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Garmezy, B.; Zhang, T.; Laccetti, A. L.; Economides, M. P.; Shah, A. Y.; Tannir, N. M.; Jonasch, E.; Msaouel, P.; Zurita, A. J.; Corn, P. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Changes in Ki-67 and cleaved caspase-3 (CC3) with short term androgen deprivation therapy (ADT) prior to prostatectomy as part of a trial in intermediate and high-risk prostate cancer (PC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Chen, Y. B.; Autio, K. A.; Carver, B. S.; Slovin, S. F.; Danila, D. C.; Scher, H. I.; Touijer, K. A.; Rathkopf, D. E.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk
    Meeting Abstract

    Choueiri, T. K.; Albiges, L.; Powles, T.; Scheffold, C.; Wang, F.; Motzer, R. J.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (MAGNITUDE)
    Meeting Abstract

    Chi, K. N.; Rathkopf, D. E.; Attard, G.; Smith, M. R.; Efstathiou, E.; Olmos, D.; Small, E. J.; Lee, J. Y.; Ricci, D. S.; Simon, J. S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Ben, Tran; Horvath, L.; Rettig, M.; Fizazi, K.; Lolkema, M. P.; Dorff, T. B.; Greil, R.; Machiels, J. P. H.; Autio, K. A.; Rottey, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914)
    Meeting Abstract

    Bex, A.; Russo, P.; Tomita, Y.; Grunwald, V.; Ramirez, L. M.; McHenry, B. M.; Motzer, R. J.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • HCRN GU15-215: A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC)
    Meeting Abstract

    Balar, A. V.; Funt, S. A.; Gupta, S.; Dudek, A. Z.; Boiles, A. R.; Vaena, D. A.; Kilari, D.; Rosenberg, J. E.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save